Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea-Reference-Cited by-同舟云学术

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

Published:2014-07-02 Issue:12 Volume:93 Page:2037-2043
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Alvarez-Larrán Alberto,Martínez-Avilés Luz,Hernández-Boluda Juan Carlos,Ferrer-Marín Francisca,Antelo María Luisa,Burgaleta Carmen,Mata M. Isabel,Xicoy Blanca,Martínez-Trillos Alejandra,Gómez-Casares M. Teresa,Durán M. Antonia,Marcote Bárbara,Ancochea Agueda,Senín Alicia,Angona Anna,Gómez Montse,Vicente Vicente,Cervantes Francisco,Bellosillo Beatriz,Besses Carles

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-014-2152-7.pdf

Reference24 articles.

1. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, EuropeanLeukemiaNet (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–70

2. Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 152:81–8

3. Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119:1363–9

4. Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones AV, Cross NC, Silver RT (2013) JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica 98:e135–7

5. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092–7

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?;Expert Opinion on Pharmacotherapy;2024-08-12

2. Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных новообразований (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.);Clinical Oncohematology;2024-07-01

3. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon;British Journal of Haematology;2024-04-08

4. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options;Annals of Hematology;2024-03-04

5. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-01-25